Once-a-Month Weight-Loss Injection: New Hope in Obesity Treatment

In research presented at the ADA 2026 Congress, the ultra-long-acting GLP-1 receptor agonist berobenatide produced significant weight loss in people with obesity or overweight and maintained its effectiveness after switching from weekly to monthly dosing.

After an initial 12-week weekly dose titration, patients taking 4.8 mg of berobenatide monthly showed an average 12.1% reduction in body weight at week 28, while a slight weight gain (0.2%) was observed in the placebo group. Notably, weight loss had still not plateaued at week 28. In the extension phase, among participants who switched from placebo to monthly berobenatide, weight loss reached 14.9% at week 60.

In the other study, which included people with type 2 diabetes who were overweight or obese, a weekly 1.6 mg dose achieved 10.2% weight loss and a 2.2% reduction in HbA1c at week 28.

Side effects were similar to those of the GLP-1 class; the most common were nausea, vomiting, diarrhea, and constipation. Most gastrointestinal side effects were mild or moderate.

Conclusion

Berobenatide stands out as a next-generation GLP-1 agonist that provides strong weight loss and glycemic control in the treatment of both obesity and type 2 diabetes. In particular, the once-a-month dosing option appears likely to improve treatment adherence and could offer an important advantage in long-term obesity management.

Source:

Monaco, K. (2026, June 8). Monthly GLP-1 for obesity promising as more manageable alternative. MedPage Today. https://www.medpagetoday.com/meetingcoverage/ada/110555